2024-09-03 - Analysis Report
## Stock Analysis Report: ABT (Abbott Laboratories)

**Company Overview:** Abbott Laboratories (ABT) is a global healthcare company that develops, manufactures, and markets a wide range of healthcare products, including medical devices, pharmaceuticals, and nutrition products.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return (ABT):** 41.96%
* **Cumulative Return (VOO):** 89.66%
* **Performance Gap:** -47.70% (ABT underperformed VOO by 47.70%)
* **Relative Divergence:** 14.85% (This indicates that ABT's current performance is near the 15th percentile of its historical performance range relative to VOO.)

**2. Recent Price Movement:**

* **Closing Price:** $113.27
* **5-day Moving Average:** $112.95
* **20-day Moving Average:** $110.90
* **60-day Moving Average:** $106.71

**3. Technical Indicators:**

* **RSI:** 82.52 (Indicates overbought conditions)
* **PPO:** 0.03 (Indicates potential for upward momentum)
* **Delta_Previous_Relative_Divergence:** -8.38 (Suggests a short-term decline in relative performance)
* **Expected_Return:** 27.09% (Represents the maximum expected return over a 5-year period for a current investment.)

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | 0.74 | $10.38 B |
| 2024-05-02 | 0.7 | $9.96 B |
| 2023-11-01 | 0.82 | $10.14 B |
| 2023-08-03 | 0.79 | $9.98 B |
| 2024-07-31 | 0.79 | $9.98 B |

* ABT's most recent earnings report (Q2 2024) showed a slight decline in EPS compared to the previous quarter, but revenue remained strong. 
* Analysts' expectations for the current quarter are not available, so it's difficult to assess the company's performance relative to those expectations. 
* Long-term growth prospects remain solid, with continued expansion in medical devices, pharmaceuticals, and nutrition products.

**5. Overall Analysis:**

ABT has underperformed the S&P 500 in recent years, but its current price is slightly above its moving averages, suggesting potential for short-term upside. However, the overbought RSI and negative relative divergence signal potential for a pullback in the near term. While the company's earnings show continued revenue growth, the decline in EPS raises concerns. 

Overall, ABT remains a solid long-term investment, but short-term price movements may be volatile. 
